Skip to main content

REVIEW article

Front. Neurol.
Sec. Experimental Therapeutics
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1471287
This article is part of the Research Topic Unraveling Ischemia-Reperfusion Injury: Advances in Injury Mechanisms and Treatment Targets View all articles

The cGAS-STING Pathway in Ischemia-Reperfusion Injury in Acute Cerebral Infarction: A New Therapeutic Opportunities?

Provisionally accepted
Jun Hu Jun Hu 1Mengxiang Tian Mengxiang Tian 2*
  • 1 The Affiliated Hospital of Yunnan University, Kunming, Yunnan Province, China
  • 2 Xiangya Hospital, Central South University, Changsha, Hunan Province, China

The final, formatted version of the article will be published soon.

    The innate immune response is the body's first line of defense against external pathogens and endogenous damage signals. The cGAS-STING pathway is a crucial component of the innate immune response, playing a key role in initiating antiviral and anti-infective immune responses by recognizing cytosolic DNA. Acute cerebral infarction is one of the leading causes of death and disability worldwide, with the primary treatment approach being the restoration of blood flow to ischemic brain tissue.However, reperfusion injury remains a significant challenge during treatment. The overactivation of the cGAS-STING pathway and its association with ischemiareperfusion injury have been confirmed in numerous studies. This article will systematically elucidate the mechanisms of the cGAS-STING pathway, its role in ischemia-reperfusion injury in acute cerebral infarction, the current research status of cGAS-STING inhibitors, and the application of nanomaterials in this context, evaluating the therapeutic potential of this pathway. (graphic abstract)

    Keywords: cGAS-STING pathway, Acute cerebral infarction, Ischemia-reperfusion, cGAS-STING inhibitor, application of nanomaterials

    Received: 29 Jul 2024; Accepted: 02 Dec 2024.

    Copyright: © 2024 Hu and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Mengxiang Tian, Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.